Study will consist of up to 28 days of screening period, 16 weeks treatment period that can be extended to 45 weeks.Approximately 40 patients will be randomized to receive SoC or LFG316 plus SoC. Patients will be included in the study if they have diagnosis of TAM and poor prognostic markers.